Jack F. Shern

The paper uses DNA methylation profiling to identify distinct subsets within rhabdomyosarcoma subtypes, revealing clinical and genetic differences among them.

This study identifies CDK8 inhibition as a therapeutic strategy for alveolar rhabdomyosarcoma by inducing myogenic differentiation and impairing tumor growth through a mechanism involving the Mediator kinase module, SAGA complex, and SIX4.

This study evaluates NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibitor therapy.

The paper identifies variable merlin inactivation in schwannomas and shows TEAD1 inhibition can reverse hippo signaling and suppress tumor growth.

This study uses plasma cfDNA fragmentomics to distinguish malignant, pre-malignant, and non-malignant NF1-associated peripheral nerve sheath tumors.